1. Search Result
Search Result
Results for "

bleeding

" in MedChemExpress (MCE) Product Catalog:

50

Inhibitors & Agonists

1

Screening Libraries

9

Peptides

1

Inhibitory Antibodies

6

Natural
Products

1

Recombinant Proteins

5

Isotope-Labeled Compounds

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0236
    6-Aminocaproic acid
    2 Publications Verification

    EACA; Epsilon-Amino-n-caproic Acid; 6-Aminohexanoic acid

    PAI-1 Metabolic Disease Cancer
    6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders .
    6-Aminocaproic acid
  • HY-12554A
    Terlipressin diacetate
    1 Publications Verification

    Vasopressin Receptor Cardiovascular Disease Inflammation/Immunology Endocrinology
    Terlipressin diacetate is a vasopressin analogue with potent vasoactive properties. Terlipressin diacetate is a highly selective vasopressin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding. Terlipressin diacetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin diacetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research .
    Terlipressin diacetate
  • HY-105240

    PMX-60056

    Factor Xa Cardiovascular Disease
    Delparantag (PMX-60056) is a salicylamide derivative and an effective unfractionated heparin (UFH) and low molecular weight heparin (LMWH) reversing agent. Delparantag shows ability to neutralize the anticoagulation and bleeding effects of UFH and LMWH .
    Delparantag
  • HY-159895

    Protease Activated Receptor (PAR) Cardiovascular Disease
    PAR4 antagonist 7 (Compound 20f) is selective PAR4 antagonist (IC50: 1.72 nM). PAR4 antagonist 7 inhibits PAR4 agonist-induced platelet aggregation. PAR4 antagonist 7 has good metabolic stability. PAR4 antagonist 7 does not show a bleeding tendency in mice .
    PAR4 antagonist 7
  • HY-B0236A

    EACA hydrochloride; Epsilon-Amino-n-caproic Acid hydrochloride; 6-Aminohexanoic acid hydrochloride

    Drug Derivative PAI-1 Metabolic Disease Cancer
    6-Aminocaproic acid hydrochloride, a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders .
    6-Aminocaproic acid hydrochloride
  • HY-144658

    Factor Xa Cardiovascular Disease
    FXIa-IN-8 is a potent and selective FXIa inhibitor with an IC50 of 14.2 nM. FXIa-IN-8 shows antithrombotic activity without increasing the bleeding risk and obvious toxicitysup>[1].
    FXIa-IN-8
  • HY-B0236R

    EACA(Standard); Epsilon-Amino-n-caproic Acid(Standard); 6-Aminohexanoic acid (Standard)

    PAI-1 Reference Standards Others Metabolic Disease Cancer
    6-Aminocaproic acid (Standard) is the analytical standard of 6-Aminocaproic acid. This product is intended for research and analytical applications. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders .
    6-Aminocaproic acid (Standard)
  • HY-12554

    Vasopressin Receptor Cardiovascular Disease Inflammation/Immunology Endocrinology
    Terlipressin is a vasopressin analogue with potent vasoactive properties. Terlipressin is a highly selective vasopressin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding. Terlipressin exerts anti-inflammatory and anti-oxidative effects. Terlipressin has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research .
    Terlipressin
  • HY-12554B

    Vasopressin Receptor Cardiovascular Disease Inflammation/Immunology Endocrinology
    Terlipressin acetate is a vasopressin analogue with potent vasoactive properties. Terlipressin acetate is a highly selective vasopressin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding. Terlipressin acetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin acetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research .
    Terlipressin acetate
  • HY-173272

    PAI-1 Cardiovascular Disease
    BT-114143 is a plasminogen activation inhibitor, with an IC50 of 8.42 μM. BT-114143 can be used in the research of hemorrhagic diseases caused by hyperfibrinolysis, such as traumatic bleeding, severe menstrual bleeding, postpartum hemorrhage, and complications of hemophilia .
    BT-114143
  • HY-B0554
    Norethindrone
    1 Publications Verification

    Norethisterone

    Progesterone Receptor Bacterial Endocrinology Cancer
    Norethindrone is a female progestin approved by FDA for the treatment of endometriosis, uterine bleeding caused by abnormal hormone levels, and secondary amenorrhea.
    Norethindrone
  • HY-151983

    Thrombin Cardiovascular Disease
    Thrombin inhibitor 6 is a potent thrombin inhibitor (IC50: 1 nM). Thrombin inhibitor 6 has the function as an anticoagulant .
    Thrombin inhibitor 6
  • HY-P2101

    Ser/Thr Protease Cardiovascular Disease
    Micropeptin 478A is a plasmin inhibitor from cyanobacteria with an IC50 of 0.1 μg/mL. Micropeptin 478A can be used to study bleeding disorders .
    Micropeptin 478A
  • HY-B0665

    Integrin Cardiovascular Disease Cancer
    Fibrin, isolated from bovine blood, is an insoluble protein produced in response to bleeding. Fibrin is the major component of the blood clot and is used for coagulation .
    Fibrin
  • HY-B1830

    E2EN

    Estrogen Receptor/ERR Endocrinology
    Estradiol enanthate (E2EN) is a shorter-acting estrogen. Estradiol enanthate is an injectable contraceptive in combination with Dihydroxyprogesterone acetophenide. Estradiol enanthate promotes withdrawal bleeding, in a pattern similar to menstruation .
    Estradiol enanthate
  • HY-B0554R
    Norethindrone (Standard)
    1 Publications Verification

    Norethisterone (Standard)

    Progesterone Receptor Bacterial Endocrinology Cancer
    Norethindrone (Standard) is the analytical standard of Norethindrone. This product is intended for research and analytical applications. Norethindrone is a female progestin approved by FDA for the treatment of endometriosis, uterine bleeding caused by abnormal hormone levels, and secondary amenorrhea.
    Norethindrone (Standard)
  • HY-B0554S2

    Norethisterone-d8

    Isotope-Labeled Compounds Endocrinology Cancer
    Norethindrone-d8 (Norethisterone-d8) is deuterium labeled Norethindrone. Norethindrone is a female progestin approved by FDA for the treatment of endometriosis, uterine bleeding caused by abnormal hormone levels, and secondary amenorrhea.
    Norethindrone-d8
  • HY-A0195

    Prostaglandin Receptor Endocrinology
    Carboprost tromethamine is the synthetic 15-methyl analogue of prostaglandin F. Carboprost tromethamine can effectively promote law contraction of the uterus and significantly reduce the amount of bleeding during and after delivery .
    Carboprost tromethamine
  • HY-116843

    (15R)-15-Methyl-PGE

    Prostaglandin Receptor Endocrinology
    (15S)-15-Methylprostaglandin E2 ((15R)-15-Methyl-PGE) is a prostaglandin E2 analog with the potential to prevent gastrointestinal bleeding and protect gastrointestinal cells .
    (15S)-15-Methylprostaglandin E2
  • HY-118557A

    S-MPEC hydrochloride

    5-HT Receptor Others
    Iferanserin hydrochloride (S-MPEC hydrochloride) is a selective serotonin receptor antagonist with the potential to inhibit internal hemorrhoids. Iferanserin hydrochloride demonstrated efficacy and tolerability in ongoing Phase IIb clinical trials, with the ability to significantly reduce patient-reported symptoms of bleeding and pruritus .
    Iferanserin hydrochloride
  • HY-N12040

    Iso-γ-fagarine

    Others Inflammation/Immunology
    γ-Isofagarine (Iso-γ-fagarine) is an alkaloid that can be isolated from the root bark of Dictamnus angustifolius. Dictamnus angustifolius has been used in the research of rheumatism, bleeding, itching, jaundice, chronic hepatitis, skin diseases, etc .
    γ-Isofagarine
  • HY-17481A

    Others Inflammation/Immunology
    Bumadizone calcium is the calcium salt of Bumadizone (HY-17481). Bumadizone calcium is a non-steroidal anti-inflammatory drug, that exhibits potential in ameliorating chronic inflammatory diseases. Bumadizone calcium is irritant to the gastric lining, which leads to gastric bleeding and ulceration .
    Bumadizone calcium
  • HY-B1830R

    E2EN (Standard)

    Reference Standards Estrogen Receptor/ERR Endocrinology
    Estradiol enanthate (Standard) is the analytical standard of Estradiol enanthate. Estradiol enanthate (E2EN) is a shorter-acting estrogen. Estradiol enanthate is an injectable contraceptive in combination with Dihydroxyprogesterone acetophenide. Estradiol enanthate promotes withdrawal bleeding, in a pattern similar to menstruation .
    Estradiol enanthate (Standard)
  • HY-P10577

    Protease Activated Receptor (PAR) Cardiovascular Disease
    RAG8 peptide is an antagonist for protease-activated receptor 4 (PAR 4), which inhibits late-stage platelet activation, and reduces thrombosis without altering hemostasis or increasing bleeding risk. RAG8 peptide can be used for atherosclerosis research .
    RAG8 peptide
  • HY-19229

    Integrin Cardiovascular Disease
    TAK-029 is a potent GP IIb/IIIa antagonist. TAK-029 has potent antithrombotic effects with bleeding time (BT) prolongation in arterial thrombosis models. TAK-029 can be used for the research of various arterial thrombotic diseases .
    TAK-029
  • HY-173268

    TAM Receptor Cardiovascular Disease Cancer
    UNC9426 (compound 12) is a potent, orally bioavailable and specific TYRO3 inhibitor with an IC50 of 2.1 nM. UNC9426 reduces platelet aggregation without increasing bleeding time. UNC9426 blocks TYRO3-dependent functions in tumor cells and macrophages .
    UNC9426
  • HY-B0554S1

    Norethisterone-13C2

    Isotope-Labeled Compounds Progesterone Receptor Bacterial Endocrinology
    Norethindrone- 13C2 (Norethisterone- 13C2) is the 13C labeled Norethindrone (HY-B0554) . Norethindrone is a female progestin approved by FDA for the treatment of endometriosis, uterine bleeding caused by abnormal hormone levels, and secondary amenorrhea .
    Norethindrone-13C2
  • HY-156613

    EP-7041

    Factor XI Infection
    Frunexian (EP-7041) is a selective and potent inhibitor of coagulation factor XI/activated factor XI, targeting to factor XIa. Frunexian exhibits antithrombotic activity, with no bleeding liability in rat mesenteric arterial puncture model. Frunexian can be used in extracorporeal membrane oxygenation (ECMO) research .
    Frunexian
  • HY-138053

    Ristomycin III

    Antibiotic Infection
    Ristocetin A is an antibiotic that is used to staphylococcal infections. However, side effects of ristocetin A included thrombocytopenia and platelet agglutination. Ristocetin A is now used in two assays related to these actions, the ristocetin cofactor assay and the ristocetin-induced platelet aggregation assay. Both assays are used in the diagnosis of von Willebrand disease and other bleeding disorders.
    Ristocetin A sulfate
  • HY-10277

    SB-424323

    Thrombin Cardiovascular Disease
    Odiparcil (SB-424323) is an orally active beta-d-thioxyloside analog with antithrombotic activity associated with a reduced risk of adverse bleeding events. Odiparcil (SB-424323) is indirect thrombin inhibitor that exerts its anticoagulant effect through activation of antithrombin II (heparin cofactor II) .
    Odiparcil
  • HY-P991211

    Factor XI Cardiovascular Disease
    Bemiltenase alfa is a hemostatic agent targeting coagulation factor X (FX). Bemiltenase alfa activates FX and promotes the conversion of prothrombin to thrombin, and thrombin can further transform fibrinogen into fibrin, forming a stable blood clot, thus exerting hemostatic activity. Bemiltenase alfa is promising for research of bleeding symptoms with hemophilia .
    Bemiltenase alfa
  • HY-19517

    Endogenous Metabolite Cardiovascular Disease
    R1663 is a factor Xa inhibitor with anticoagulant activity. R1663 does not affect bleeding time. The pharmacodynamic effects (such as inhibition of thrombin generation) and plasma concentrations of R1663 are dose-dependent. R1663 prolongs clotting time in a concentration-dependent manner and inhibits the peak height of thrombin generation and endogenous thrombin potential .
    R1663
  • HY-A0195R

    Prostaglandin Receptor Endocrinology
    Carboprost (tromethamine) (Standard) is the analytical standard of Carboprost (tromethamine). This product is intended for research and analytical applications. Carboprost tromethamine is the synthetic 15-methyl analogue of prostaglandin F. Carboprost tromethamine can effectively promote law contraction of the uterus and significantly reduce the amount of bleeding during and after delivery .
    Carboprost (tromethamine) (Standard)
  • HY-109091
    Lanraplenib
    2 Publications Verification

    GS-9876

    Syk Inflammation/Immunology Cancer
    Lanraplenib (GS-9876) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib (GS-9876) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans .
    Lanraplenib
  • HY-P0004R

    Adenylate Cyclase Others
    Lysipressin (Standard) is the analytical standard of Lysipressin. This product is intended for research and analytical applications. Lysipressin (Lysine vasopressin) is antidiuretic hormone that have been found in pigs and some marsupial families. Lysipressin induces contraction of the rabbit urinary bladder smooth muscle, activate adenylate-cyclase .
    Lysipressin (Standard)
  • HY-P0004
    Lysipressin
    2 Publications Verification

    Lysine vasopressin; [Lys8]-Vasopressin

    Adenylate Cyclase Oxytocin Receptor Cardiovascular Disease Neurological Disease
    Lysipressin (Lysine vasopressin) is antidiuretic hormone that have been found in pigs. Lysipressin activates Oxytocin receptors and adenylate-cyclase. Lysipressin adjusts blood pressure and heart rate. Lysipressin shows antinociceptive activity .
    Lysipressin
  • HY-P0004A
    Lysipressin acetate
    2 Publications Verification

    Lysine vasopressin acetate; [Lys8]-Vasopressin acetate

    Adenylate Cyclase Others
    Lysipressin (Lysine vasopressin) acetate is antidiuretic hormone that have been found in pigs and some marsupial families. Lysipressin acetate induces contraction of the rabbit urinary bladder smooth muscle, activate adenylate-cyclase .
    Lysipressin acetate
  • HY-B0554S

    Isotope-Labeled Compounds Progesterone Receptor Endocrinology
    Norethindrone-d6 is the deuterium labeled Norethindrone. Norethindrone is a female progestin approved by FDA for the treatment of endometriosis, uterine bleeding caused by abnormal hormone levels, and secondary amenorrhea. Norethindrone-d6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Norethindrone-d6
  • HY-113958

    LM-2219

    VD/VDR Others
    Difethialone (LM-2219) is an anticoagulant rodenticide. Difethialone shows high rodenticide activity in warfarin-sensitive and resistant strains of rats and mice. Difethialone interferes with the circulation of vitamin K in the liver, preventing the synthesis of coagulation factors, resulting in the inability of the blood to coagulate properly, ultimately causing internal bleeding and death. Difethialone can be used in studies of ecological impacts .
    Difethialone
  • HY-109091B
    Lanraplenib succinate
    2 Publications Verification

    GS-9876 succinate

    Syk Inflammation/Immunology Cancer
    Lanraplenib succinate (GS-9876 succinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib succinate (GS-9876 succinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans .
    Lanraplenib succinate
  • HY-123400A

    iso-DTTX30; iso-DT-TX 30 SE

    Prostaglandin Receptor Cardiovascular Disease
    Iso-Samixogrel (iso-DTTX30) is a combined thromboxane A2 receptor blocker and thromboxane synthetase inhibitor that exhibits potent antithrombotic activity. Iso-Samixogrel effectively eliminates recurrent arterial thrombus formation and inhibits collagen-induced platelet aggregation ex vivo. Iso-Samixogrel also prolongs sublingual bleeding time, demonstrating its biological efficacy in managing thrombosis.
    iso-Samixogrel
  • HY-109091A

    GS-9876 monosuccinate

    Syk Inflammation/Immunology Cancer
    Lanraplenib monosuccinate (GS-9876 monosuccinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib monosuccinate (GS-9876 monosuccinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans .
    Lanraplenib monosuccinate
  • HY-117464

    MMP Cardiovascular Disease
    CM-352 (compound 5) is an inhibitor of matrix metalloproteinases (MMPs) (MMP-3: IC50=15 nM; MMP-10: IC50=12 nM). CM-352 has significant antifibrinolytic activity (EC50=0.7 nM) and can significantly prolong blood coagulation time. CM-352 can be used in anti-bleeding research .
    CM-352
  • HY-113958R

    TrxR Others
    Difethialone (Standard) is the analytical standard of Difethialone. This product is intended for research and analytical applications. Difethialone (LM-2219) is an anticoagulant rodenticide. Difethialone shows high rodenticide activity in warfarin-sensitive and resistant strains of rats and mice. Difethialone interferes with the circulation of vitamin K in the liver, preventing the synthesis of coagulation factors, resulting in the inability of the blood to coagulate properly, ultimately causing internal bleeding and death. Difethialone can be used in studies of ecological impacts .
    Difethialone (Standard)
  • HY-B0236S

    EACA-d6; Epsilon-Amino-n-caproic acid-d6; 6-Aminohexanoic acid-d6

    Isotope-Labeled Compounds Metabolic Disease
    6-Aminocaproic acid-d6 is deuterium labeled 6-Aminocaproic acid. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders .
    6-Aminocaproic acid-d6
  • HY-B0236S1

    EACA-d10; Epsilon-Amino-n-caproic Acid-d10; 6-Aminohexanoic acid-d10

    Isotope-Labeled Compounds Metabolic Disease
    6-Aminocaproic acid-d10 is the deuterium labeled 6-Aminocaproic acid. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders .
    6-Aminocaproic acid-d10
  • HY-111755

    P2Y Receptor Cardiovascular Disease
    Oral antiplatelet agent 1 is a potent P2Y12 receptor antagonist. Oral antiplatelet agent 1 exhibits excellent antiplatelet aggregation potency with an IC50 value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. Oral antiplatelet agent 1 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. Oral antiplatelet agent 1 can be used to research thromboembolic disorders .
    Oral antiplatelet agent 1
  • HY-125856A

    BMS-986177 TFA; JNJ-70033093 TFA

    Factor Xa Cardiovascular Disease
    Milvexian TFA (BMS-986177 TFA) is a factor XIa inhibitor with biological activity to prevent venous thromboembolism. Milvexian TFA was effective in reducing the occurrence of venous thromboembolism in patients undergoing knee replacement surgery. Milvexian TFA has good selectivity and shows significant inhibitory effects on plasma kallikrein and trypsin. Milvexian TFA has a bioavailability of 32%, which means it has a high absorption rate in the body. Milvexian TFA showed a relatively low risk of bleeding in clinical trials .
    Milvexian TFA
  • HY-167848

    XL-118

    Others Cardiovascular Disease
    DMP-728 free base (XL-118) is a highly potent and selective GPIIb/IIIa antagonist with antiplatelet and antithrombotic activities. DMP-728 free base can inhibit ADP-induced human platelet aggregation in vitro, with an IC50 of 46 nmol/L, and can significantly reduce the interaction between fibrinogen and human platelets or Binding of purified human GPIIb/IIIa receptors. DMP-728 free base exhibits dose-dependent antiplatelet effects in anesthetized mongrel dogs, effectively inhibiting ADP-induced platelet aggregation and prolonging template bleeding time .
    DMP-728 free base
  • HY-A0119
    Nitroprusside disodium dihydrate
    Maximum Cited Publications
    8 Publications Verification

    Sodium nitroprusside dihydrate; Sodium Nitroferricyanide(III) Dihydrate

    Autophagy Cardiovascular Disease Cancer
    Nitroprusside disodium dehydrate (Sodium nitroprusside dihydrate) is a vasodilator that available for the research of acute hypertension, heart failure. Nitroprusside disodium dehydrate induces autophagy in glutathione-depleted osteoblasts. Nitroprusside disodium dehydrate acts as a nitric oxide (NO) donor in a rat intestinal ischemia reperfusion model .
    Nitroprusside disodium dihydrate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: